First-Line Treatment for Insomnia

Introduction to CBT-I

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for all adults with chronic insomnia, to be initiated before any pharmacological intervention, due to its superior long-term efficacy and minimal risk of adverse effects 1, 2, 3
CBT-I demonstrates sustained benefits lasting up to 2 years, addressing the underlying mechanisms maintaining insomnia rather than just suppressing symptoms 1, 3

The American Academy of Sleep Medicine suggests that key components of effective CBT-I include sleep restriction therapy, stimulus control, cognitive restructuring to address maladaptive thoughts about sleep, and sleep hygiene education, although the latter is insufficient as monotherapy 1, 2, 3

CBT-I can be delivered through multiple effective formats, including in-person individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books, addressing common barriers such as cost, geographic limitations, and provider availability 1, 2

The American Academy of Sleep Medicine recommends short-intermediate acting benzodiazepine receptor agonists (BzRAs) or ramelteon as first-line medications when pharmacotherapy is necessary, with specific dosages for sleep onset and maintenance insomnia 2
For sleep onset insomnia, recommended medications include zaleplon 10 mg, zolpidem 10 mg (5 mg in elderly), and ramelteon 8 mg 2
For sleep maintenance insomnia, recommended medications include eszopiclone 2-3 mg, zolpidem 10 mg, and temazepam 15 mg 2

The American Academy of Sleep Medicine advises against using over-the-counter antihistamines, antipsychotics, long-acting benzodiazepines, herbal supplements, and melatonin as first-line treatments due to lack of efficacy, increased risks, or insufficient evidence 2, 4

The treatment algorithm involves initiating CBT-I as the primary intervention, adding short-term pharmacotherapy if necessary, and selecting medication based on symptom pattern, with regular follow-up to assess effectiveness and side effects 1, 2, 3

All hypnotics carry significant risks, including daytime impairment, complex sleep behaviors, falls and fractures, dependence, and withdrawal, particularly in elderly patients 2
Elderly patients should use lower doses, avoid benzodiazepines, and consider alternative medications such as trazodone or orexin receptor antagonists 2, 5

Common pitfalls include starting with medications before attempting CBT-I, using sleep hygiene education alone, prescribing over-the-counter antihistamines or herbal supplements, and continuing pharmacotherapy long-term without reassessment 1, 2, 3, 4

Regular follow-up is essential to assess effectiveness, side effects, and need for medication adjustments, with evaluation for underlying sleep disorders if insomnia persists beyond 7-10 days of treatment 2